VolitionRx’s (VNRX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of VolitionRx (NYSE:VNRX) in a research note released on Thursday,Benzinga reports. They currently have a $5.00 price objective on the stock.

A number of other research analysts also recently commented on the company. HC Wainwright lowered their target price on VolitionRx from $2.50 to $1.50 and set a “buy” rating on the stock in a research note on Monday, November 17th. Maxim Group lowered shares of VolitionRx from a “buy” rating to a “hold” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, VolitionRx currently has an average rating of “Buy” and a consensus target price of $3.17.

VolitionRx Stock Performance

VNRX stock opened at $0.30 on Thursday. VolitionRx has a 52 week low of $0.27 and a 52 week high of $0.94. The stock has a market cap of $36.80 million, a P/E ratio of -0.83 and a beta of 1.26. The firm has a 50 day simple moving average of $0.43 and a 200 day simple moving average of $0.58.

Insiders Place Their Bets

In other VolitionRx news, CEO Cameron John Reynolds acquired 110,000 shares of the business’s stock in a transaction on Tuesday, October 14th. The stock was purchased at an average price of $0.51 per share, for a total transaction of $56,100.00. Following the transaction, the chief executive officer owned 2,534,847 shares in the company, valued at $1,292,771.97. This trade represents a 4.54% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Guy Archibald Innes purchased 96,153 shares of VolitionRx stock in a transaction that occurred on Tuesday, October 14th. The shares were bought at an average price of $0.51 per share, for a total transaction of $49,038.03. Following the transaction, the director owned 1,062,967 shares in the company, valued at $542,113.17. This represents a 9.95% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 289,229 shares of company stock worth $146,557 over the last quarter. Company insiders own 10.40% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

A number of institutional investors and hedge funds have recently modified their holdings of the business. Silverberg Bernstein Capital Management LLC grew its position in shares of VolitionRx by 15.6% in the 3rd quarter. Silverberg Bernstein Capital Management LLC now owns 232,082 shares of the company’s stock valued at $157,000 after purchasing an additional 31,300 shares during the period. Blair William & Co. IL bought a new position in shares of VolitionRx in the second quarter valued at $30,000. Virtu Financial LLC acquired a new position in shares of VolitionRx during the 3rd quarter worth about $28,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of VolitionRx during the 2nd quarter worth approximately $52,000. Finally, Citadel Advisors LLC lifted its stake in shares of VolitionRx by 70.1% during the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the company’s stock worth $224,000 after buying an additional 135,775 shares during the last quarter. 8.09% of the stock is owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.